L-Glutamine ( DrugBank: L-Glutamine, Glutamine )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
113	Muscular dystrophy	1
299	Cystic fibrosis	1

113. Muscular dystrophy

---

Clinical trials : 622 /  Drugs : 485 - (DrugBank : 99) / Drug target genes : 59 - Drug target pathways : 168

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00296621 (ClinicalTrials.gov)	February 2006	23/2/2006	Effect of Oral Glutamine on Muscle Mass and Function in Duchenne Muscular Dystrophy	Efficacy Study of Oral Glutamine Supplementation in Duchenne Muscular Dystrophy	Muscular Dystrophy, Duchenne	Drug: L-Glutamine;Drug: placebo	Assistance Publique - Hôpitaux de Paris	NULL	Completed	N/A	N/A	Male	30	Phase 2	France

299. Cystic fibrosis

---

Clinical trials : 1,696 /  Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2007-006204-37-GB (EUCTR)	03/07/2008	09/05/2008	Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CF	Glutamine supplementation for cystic fibrosis: a parallel group randomized controlled trial - Glutamine and CF	Cystic fibrosis MedDRA version: 9.1;Level: LLT;Classification code 10011762;Term: Cystic fibrosis	Product Name: Glutamine Product Code: none Other descriptive name: L-Glutamine	University of Nottingham	NULL	Not Recruiting			Female: yes Male: yes	44	Human pharmacology (Phase 1): no Therapeutic exploratory (Phase 2): no Therapeutic confirmatory - (Phase 3): no Therapeutic use (Phase 4): yes	United Kingdom